Novel Mitotic Targets and Their Small-Molecule Inhibitors

Author(s): Alexandre V. Ivachtchenko, Alex S. Kiselyov, Sergey E. Tkachenko, Yan A. Ivanenkov, Konstantin V. Balakin

Journal Name: Current Cancer Drug Targets

Volume 7 , Issue 8 , 2007

Become EABM
Become Reviewer


With several successful anticancer drugs on the market and numerous compounds in clinical developments, antimitotic agents represent an important category of anticancer agents. However, clinical utility of the tubulin-binding agents is somewhat limited due to multiple drug resistance (MDR), poor pharmacokinetics and therapeutic index. There is ongoing need for the modulators of other intracellular targets that result in the same anti-mitotic effect without adverse effects of “traditional” tubulin binders. This review describes progress made to-date in development of novel and emerging biotargets affecting the mitotic events, and their small-molecule modulators.

Keywords: Antimitotic agents, mitotic kinesins, mitotic kinases, separase

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [766 - 784]
Pages: 19
DOI: 10.2174/156800907783220499
Price: $65

Article Metrics

PDF: 4